Core Insights - The chairman of Dana Biotech, Zhou Zeqi, emphasizes the importance of long-term investment in core technology for sustainable development in the biopharmaceutical industry [2][3] - Dana Biotech, founded in 2014, has become a leader in early diagnosis of fungal diseases in China and is set to be the first IVD company listed on the Beijing Stock Exchange in November 2025 [2][3] Company Development - Dana Biotech was established to address the significant gap in pathogen diagnosis, particularly in fungal diseases, which have high misdiagnosis and mortality rates [3][4] - The company’s first core product, derived from the horseshoe crab's blood, allows for rapid differentiation between fungal and bacterial infections, significantly improving diagnostic speed and accuracy [4][5] Market Potential - The market for invasive fungal disease diagnostic reagents in China is projected to grow from 240 million yuan in 2018 to 3.03 billion yuan by 2030, with a compound annual growth rate of 23.5% [4][6] - Dana Biotech has developed a "5G+ Joint Detection Scheme" that includes seven core testing projects, covering various fungal diseases and has been adopted by over 1,300 hospitals [5][6] Innovation and R&D - As of October 2025, Dana Biotech has obtained 91 domestic and international patents, including 48 invention patents, and has developed a robust innovation system supported by over 30 million yuan in annual R&D investment [6][7] - The company has established a stable R&D team of over 80 members and has developed over 70 new products through a systematic approach from laboratory to clinical application [7][8] Future Directions - The funds raised from the upcoming IPO will be allocated to the construction of a new headquarters and further R&D, focusing on invasive fungal infections and AI applications in diagnostics [8][9] - AI technology is expected to enhance diagnostic efficiency and accuracy, providing multidimensional diagnostic results to assist physicians in treatment decisions [8][9] Strategic Vision - Dana Biotech aims to become a leader in the fungal diagnostics industry, leveraging core technologies to address challenges in precise diagnosis and treatment in the health sector [9]
丹娜生物董事长周泽奇：以持续创新攻坚真菌诊断难题